Consistent with our results that mimicked therapy and anti‐inflammation with induction of Ptx3 loss and αPTX3i administration (Figures 2 and 5), the dose and timing of PTX3‐based therapy in lung fibrosis must be investigated in the future. This evidence concerns the gene PTX3 and pulmonary fibrosis.